Reading the tape
NASDAQ: VRDN
Viridian Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$1.53B
52w High
$34.29
52w Low
$11.76
P/E
-5.10
Volume
9.91M
Outstanding Shares
84.85M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
1Y Price: 44.59%Revenue (TTM): 23,382.78%FCF (TTM): -8.37%P/S: 58th pct
What changed
The stock rose 44.59% over the last year. Revenue grew 23,382.78% over the trailing twelve months. Operating margin moved from -111,591.06% to -543.86%. Free cash flow declined 8.37% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 58th percentile of their historical P/S range.
What would invalidate this read
Operating margin is at -543.86%. Revenue grew 23,382.78% — this thesis depends on that trajectory holding. Despite the price move, free cash flow fell 8.37%, which is worth watching as a leading indicator of future pressure. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases.
CEOStephen F. Mahoney
SectorHealthcare
IndustryBiotechnology
Employees143
IPO dateJun 18, 2014
Valuation
Forward P/E—
EV/EBITDA-7.36
Enterprise value$2.48B
Stock splits
Nov 13, 2020↓ Reverse
Every 15 shares became 1
Nov 7, 2016↓ Reverse
Every 15 shares became 1
Profitability & growth
Revenue growth95.83%
Gross margin99.35%▼1.64%vs FY2024
Operating margin-543.86%▲99.48%vs FY2024
ROE-47.44%▼18.03%vs FY2024
Analyst consensus
RatingBuy
Target price$42.67▲137.32%
13
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$1.06 · Revenue est $36.08K
View